Sharon Taft-Benz

3 weeks ago | pubs.acs.org | Mohammad Hossain |Anirban Ghoshal |Sharon Taft-Benz

IntroductionClick to copy section linkSection link copied!Covalent enzyme inhibitors have been developed as effective direct acting drugs to combat viral infections. (1) Examples include nirmatrelvir, which targets the main cysteine protease of SARS-CoV-2 and is used to treat COVID-19. (2) Likewise, boceprevir, and narlaprevir are covalent inhibitors of hepatitis C virus (HCV) NS3/4A serine protease and are effective in the treatment of chronic HCV infections.